Forthcoming Special Issue on Circulating Biomarkers for Cardiovascular Diseases
A special issue on “Circulating Biomarkers for Cardiovascular Diseases” will be published by Acta Pharmacologica Sinica in May 2018. Authors are warmly invited to submit original articles or reviews related to the topics stated below.
Main Purpose of the Special Issue
Cardiovascular diseases (CVD) remain to be the No. 1 killer in major industrial countries and also increasingly become the gravest public health burden in the emerging economies with large populations such as China and India. There are still significant gaps and huge demands for more reliable and innovative methods and tools for diagnosis and evidence-guided management of CVD. Under this context, the basic research and clinical use of biomarkers have gained a tremendous momentum in the past decade. The use of single or multiple biomarkers as reliable and reproducible indicatives of the risk, severity, and progression stage of CVD greatly enhances the diagnostic decision and prognostic ability of emergency department physicians, cardiologists, and cardiothoracic surgeons in their routine patient care duties. The prudential utilization of valid biomarker in clinical practice can reduce time and costs for an accurate diagnosis and proper personalized therapy of CVD patients.
Accordingly this Special Issue provides a forum for high quality original research and review articles to showcase the most recent advances in translational research and clinical practices on a wide-spectrum array of conventional as well as novel cardiovascular biomarkers. Coverage of this Special Issue encompasses various forms of large or small molecules, such as protein, peptide, gene, microRNAs, and metabolic by-products that are released from injured cardiovascular tissues into blood stream during various CVD events.
1. New advancement of conventional biomarkers in diagnosis of hypertension, coronary artery disease, heart failure, cerebrovascular disease, aneurysmal disease, aortic dissection, peripheral arterial disease, etc.
2. Studies on novel candidate biomarkers for CVD.
3. Use of biomarkers for prediction of cardiovascular risk and events.
4. Effect of pharmacotherapy and comorbid diseases on circulating cardiovascular biomarkers.
5. Role of microRNAs and other gene products as new generation of cardiovascular biomarkers.
6. Studies on pathophysiology and molecular biology mechanisms for validating novel candidate cardiovascular biomarkers.
7. Reports and meta-analysis on recent biomarker-related clinical trials.
8. Methodological investigation or bioengineering aspects of CVD biomarkers.
Prof. Lei Xi, Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, USA
Dr. George Kouvelos, Department of Vascular Surgery, University of Thessaly, Larissa, Greece
Prof. Nazerano Paolocci, Division of Cardiology, Johns Hopkins University, Baltimore, USA